India's Cipla assures 1.5 million Tamiflu supplies amid swine flu eruption
India-based generic drug maker Cipla Ltd. said Monday (April 27) it can supply 1.5 million doses of flu treatment Tamiflu in four-six weeks' time.
"We have stocks in readiness," Amar Lulla, Cipla's chief executive and joint managing director, told Dow Jones Newswires.
The company will look to export Tamiflu if there is a need, Lulla said, adding, Cipla is yet to hear from the Indian government on stockpiling the drug.
Cipla sells a generic version of Tamiflu to government-run hospitals in India. Its version of the drug is priced at INR1,000 for a course of 10 capsules.
At least 103 people have died from severe pneumonia caused by a flu-like illness in Mexico, according to the World Health Organization.